SCHEDULE 2 REGULATION 21 5. Growth Hormone (GH) and its releasing factors including: • Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; • Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; • GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2). Additional prohibited growth factors: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulinlike Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. S3. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.; Including, but not limited to: Fenoterol; formoterol; higenamine; indacaterol; olodaterol; procaterol; reproterol; salbutamol; salmeterol; terbutaline; vilanterol. Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours); , not to exceed 800 micrograms every 12 hours; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic dose (by inhalation) up to the maximum dose indicated above. S4. HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 4-androstene-3,6,17 trione (6-oxo); aminoglutethimide; anastrozole; androsta-1,4,6-triene-3,17-dione (androstatrienedione); Last update: 3 January, 2017 480
World Rugby Handbook
To see the actual publication please follow the link above